A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

PURPOSE: Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%). METHODS: This randomized, multi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Baselga, José, Morales, Serafin M., Awada, Ahmad, Blum, Joanne L., Tan, Antoinette R., Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J., Haddad, Tufia, Ciruelos, Eva M., Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, Rugo, Hope S.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448790/
https://ncbi.nlm.nih.gov/pubmed/28324268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4199-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares